新聞CSL Behring AG acquired Calimmune for $91M on Aug 28th '17.CSL Behring, the US subsidiary of Australia-based CSL has agreed to acquire Calimmune, an American biotechnology company focused on developing ex vivo hematopoietic stem cell (HSC) gene therapy.
新聞Calimmune is developing stem-cell gene therapy on Jan 1st '06.Calimmune, co-founded by UA biology grad and entrepreneur Louis Breton in 2006, is developing stem-cell gene therapy to strengthen patients’ own immune systems.
新聞CSL Limited acquired Calimmune for $91M on Aug 1st '17.Blood product and vaccine manufacturer CSL Limited (ASX: CSL) this morning announced that it has agreed to acquire US biotechnology Calimmune for the sum of $91 million.
